JP2020508339A5 - - Google Patents

Download PDF

Info

Publication number
JP2020508339A5
JP2020508339A5 JP2019546291A JP2019546291A JP2020508339A5 JP 2020508339 A5 JP2020508339 A5 JP 2020508339A5 JP 2019546291 A JP2019546291 A JP 2019546291A JP 2019546291 A JP2019546291 A JP 2019546291A JP 2020508339 A5 JP2020508339 A5 JP 2020508339A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
dosage form
diuretic
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019546291A
Other languages
English (en)
Japanese (ja)
Other versions
JP7223701B2 (ja
JP2020508339A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/078371 external-priority patent/WO2018153513A1/en
Publication of JP2020508339A publication Critical patent/JP2020508339A/ja
Publication of JP2020508339A5 publication Critical patent/JP2020508339A5/ja
Application granted granted Critical
Publication of JP7223701B2 publication Critical patent/JP7223701B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019546291A 2017-02-27 2017-11-06 ４－ピリミジンスルファミド誘導体の、エンドセリン関連疾患治療用の有効成分との合剤 Active JP7223701B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/054489 2017-02-27
EP2017054489 2017-02-27
EP2017061487 2017-05-12
EPPCT/EP2017/061487 2017-05-12
PCT/EP2017/078371 WO2018153513A1 (en) 2017-02-27 2017-11-06 Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases

Publications (3)

Publication Number Publication Date
JP2020508339A JP2020508339A (ja) 2020-03-19
JP2020508339A5 true JP2020508339A5 (https=) 2020-12-17
JP7223701B2 JP7223701B2 (ja) 2023-02-16

Family

ID=60268369

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019546291A Active JP7223701B2 (ja) 2017-02-27 2017-11-06 ４－ピリミジンスルファミド誘導体の、エンドセリン関連疾患治療用の有効成分との合剤
JP2019546286A Pending JP2020508338A (ja) 2017-02-27 2018-02-26 ４−ピリミジンスルファミド誘導体の結晶形
JP2022201112A Active JP7520951B2 (ja) 2017-02-27 2022-12-16 ４－ピリミジンスルファミド誘導体の結晶形

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019546286A Pending JP2020508338A (ja) 2017-02-27 2018-02-26 ４−ピリミジンスルファミド誘導体の結晶形
JP2022201112A Active JP7520951B2 (ja) 2017-02-27 2022-12-16 ４－ピリミジンスルファミド誘導体の結晶形

Country Status (28)

Country Link
US (5) US11174247B2 (https=)
EP (3) EP3658140B1 (https=)
JP (3) JP7223701B2 (https=)
KR (3) KR102568472B1 (https=)
CN (3) CN110325186A (https=)
AU (2) AU2017400276B2 (https=)
BR (2) BR112019017658A2 (https=)
CA (2) CA3053991A1 (https=)
CL (3) CL2019002470A1 (https=)
DK (2) DK3658140T3 (https=)
ES (2) ES3038007T3 (https=)
FI (2) FI3658140T3 (https=)
HR (2) HRP20250921T1 (https=)
HU (2) HUE072288T2 (https=)
IL (4) IL268850B2 (https=)
LT (2) LT3658140T (https=)
MA (2) MA49664A (https=)
MX (3) MX392313B (https=)
MY (2) MY199557A (https=)
PH (2) PH12019501938A1 (https=)
PL (2) PL3658140T3 (https=)
PT (2) PT3658140T (https=)
RS (2) RS67082B1 (https=)
SG (3) SG11201907435PA (https=)
SI (2) SI3658140T1 (https=)
TW (2) TWI854353B (https=)
UA (1) UA126122C2 (https=)
WO (2) WO2018153513A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2958110A1 (en) * 2014-08-14 2016-02-18 Vivus, Inc. Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
KR102568472B1 (ko) 2017-02-27 2023-08-18 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물
KR20260037123A (ko) 2017-11-30 2026-03-17 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용
JP7312262B2 (ja) 2018-09-28 2023-07-20 フロー メディカル コーポレイション カテーテル装置
CA3123990A1 (en) * 2018-12-21 2020-06-25 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
CN112569357B (zh) * 2019-09-30 2023-03-28 深圳奥萨制药有限公司 双重内皮素受体拮抗剂与利尿剂的组合物
CN112679441A (zh) * 2019-10-18 2021-04-20 普济生物科技（台州）有限公司 阿普昔腾坦的晶型、制备方法及其用途
AU2020378025A1 (en) * 2019-11-07 2022-06-23 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of Aprocitentan, preparation method therefor and use thereof
WO2021237004A1 (en) 2020-05-21 2021-11-25 Teva Pharmaceuticals International Gmbh Solid state forms of aprocitentan and process for preparation thereof
CN115803028A (zh) 2020-07-10 2023-03-14 阿斯利康(瑞典)有限公司 用于治疗慢性肾病的齐泊腾坦和达格列净的组合
CN114644595A (zh) * 2020-12-19 2022-06-21 普济生物科技（台州）有限公司 阿普昔腾坦的无定型态、其药物组合物和用途
WO2023111797A1 (en) * 2021-12-17 2023-06-22 Janssen Biotech, Inc. Pyrimidine sulfamide derivatives and process for manufacturing them
AU2023276826A1 (en) 2022-05-22 2025-01-09 Idorsia Pharmaceuticals Ltd Aprocitentan for the treatment of hypertension
US20250340520A1 (en) 2022-05-25 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide
WO2024140425A1 (zh) * 2022-12-30 2024-07-04 苏州科睿思制药有限公司 一种阿普昔腾坦晶型及其制备方法和用途
KR20250152723A (ko) 2024-04-16 2025-10-24 경북대학교 산학협력단 신규한 피리미딘 유도체 화합물 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569116A (en) 1896-10-06 Washlngtorf
DK0634175T3 (da) * 1993-07-15 2001-04-30 Hoffmann La Roche Farmaceutisk kombination, der indeholder en hæmmer af renin-angiotensin-systemet og en endothelin-antagonist
HU229403B1 (en) 2000-12-18 2013-12-30 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
AU2007217100A1 (en) 2006-02-17 2007-08-30 Gilead Colorado, Inc. Antihypertensive therapy
US20070293552A1 (en) 2006-06-15 2007-12-20 Gorczynski Richard J Antihypertensive therapy method
PE20080991A1 (es) 2006-06-27 2008-09-05 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
EP3708163A1 (en) 2009-03-31 2020-09-16 Ligand Pharmaceuticals, Inc. Use of sparsentan for the treatment of chronic inflammatory diseases
CN102614189B (zh) * 2012-04-17 2014-10-22 北京哈三联科技股份有限公司 含缬沙坦、氨氯地平和氢氯噻嗪的微丸药物组合
EP2907811A1 (en) 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
JP2017534634A (ja) 2014-11-07 2017-11-24 アッヴィ・インコーポレイテッド 体液貯留の予測因子を使用してｃｋｄを処置する方法
WO2017185142A1 (en) 2016-04-29 2017-11-02 Adelaide Research & Innovation Pty Ltd Method for preventing and/or treating atrial fibrillation
KR102568472B1 (ko) 2017-02-27 2023-08-18 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물
KR20260037123A (ko) 2017-11-30 2026-03-17 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용
CA3123990A1 (en) * 2018-12-21 2020-06-25 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension

Similar Documents

Publication Publication Date Title
JP2020508339A5 (https=)
CA3053991A1 (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
JP2021504423A5 (https=)
JP2020508338A5 (https=)
JP2019517542A5 (https=)
JP2022180461A5 (https=)
IL274943B1 (en) Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
FI3661514T3 (fi) Mavakamteeni käytettäväksi hypertrofisen kardiomyopatian hoidossa
JP2015526458A5 (https=)
JP2010518122A5 (https=)
CN101450211A (zh) 复方降压制剂
BRPI0716302A2 (pt) composiÇço farmacÊutica oral de liberaÇço atrasda por tempo de intervalo e mÉtodo para preparar um composiÇço farmacÊutica oral de liberaÇço atrasada por tempo de intervalo
JP2020169187A (ja) 僧帽弁疾患による無症候性心不全の患者の心臓サイズの減少及び／又は臨床的症候の発生の遅延のためのピモベンダンの使用
JP2019536816A5 (https=)
JP2019533660A5 (https=)
CN113230411B (zh) 一种阿利沙坦酯或其盐与钙离子通道拮抗剂的复方药物组合物
JP2008524136A5 (https=)
JP2019218379A5 (https=)
JP2015522077A5 (https=)
JP6509729B2 (ja) 慢性腎臓病の進行抑制又は改善剤
EA201100916A1 (ru) Комбинация инсулина с триазиновыми производными и их применение для лечения диабета
JP2008534473A5 (https=)
JP2006524699A5 (https=)
CN101416966B (zh) 一种治疗高血压的药物组合物
CN113289023B (zh) 一种阿利沙坦酯或其盐与利尿剂的药物组合物